-

Denise Vitola Joins Bayer Communications Team

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer today announced Denise Vitola is joining the Bayer Communications Team as Vice President of Brand Integration, PR, Social and Influencer for Consumer Health. In this role, Vitola will be responsible for leading strategy for integrated brand PR, social media and influencer marketing for all Consumer Health U.S. brands.

For the last two years, Vitola has played an integral role as a consultant leading internal communications and brand PR for Bayer Consumer Health North America, including spearheading the advancement of influencer marketing and organic social for Consumer Health North America and launching new integrated campaigns for Midol®, Bayer® Aspirin, AleveX™, One-A-Day®, Claritin® and Alka-Seltzer®.

Vitola will report to Beth Roden, SVP and Head of Communications – Bayer U.S. and Head of Communications, Consumer Health North America. Denise will also be a member of the U.S. Corporate Communications Leadership Team, driving reputation, digital excellence and integrated communications.

“Over the last two years, Denise has elevated and brought new relevance to Bayer Consumer Health North America’s largest brands that have been around for decades through integrated marketing, including impactful influencer and social media programs, to truly deliver exceptional results,” Roden said. “We are thrilled she is now officially a member of the Bayer Communications team and will continue to drive our successful integrated communications that has been an essential part of reaching our consumers and driving awareness of our brands.”

Vitola has over a decade and a half of award-winning, branding and integrated marketing experience. She has a broad background working on clients in consumer, health, tech and financial services. Prior to working with Bayer Consumer Health North America, Vitola helped drive innovation and strategy through integrated, social and holistic marketing campaigns for global brands. Earlier this year, Vitola was named a 2021 PRNews Top Woman in PR.

About Bayer

Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Its products and services are designed to help people and planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Bayer is committed to drive sustainable development and generate a positive impact with its businesses. At the same time, the Group aims to increase its earning power and create value through innovation and growth. The Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2020, the Group employed around 100,000 people and had sales of 41.4 billion euros. R&D expenses before special items amounted to 4.9 billion euros. For more information, go to www.bayer.com.

Social Media Channels

- Facebook: BayerUnitedStates
- Twitter: BayerUS
- Instagram: BayerUS
- YouTube: BayerUS

Bayer® and the Bayer Cross® are registered trademarks of Bayer.

Contacts

Danielle Goonan
danielle.goonan@bayer.com

Bayer


Release Versions

Contacts

Danielle Goonan
danielle.goonan@bayer.com

More News From Bayer

Bayer Starts Phase IIa Study for Treatment of Patients With Alport Syndrome

BERLIN--(BUSINESS WIRE)--Bayer announced today initiation of a Phase IIa clinical trial with BAY 3401016, an investigational monoclonal antibody with potential to block a protein called Semaphorin 3A (Sema3A), which is thought to be involved in the progression of kidney damage in Alport Syndrome (AS), a rare genetic disorder. The first-in-patient study, ASSESS, is a randomized, double-blind, placebo-controlled, group-comparison trial (NCT07211685), with an extension phase, which will investigat...

RSNA25: Pediatric Study for Bayer's Investigational MRI Contrast Agent Gadoquatrane Meets Primary and Secondary Endpoints

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer, a global leader in radiology, today revealed results from the QUANTI Pediatric study, adding to the pharmacokinetic, safety and efficacy data of the investigational low-dose MRI gadolinium-based contrast agent (GBCA) gadoquatrane. QUANTI Pediatric evaluated gadoquatrane in children with known or suspected disease undergoing contrast-enhanced magnetic resonance imaging (MRI) at a gadolinium dose of 0.04 mmol Gd/kg body weight, representing a dose reduction...

Bayer Starts New Phase III Study with Mirena® for the Treatment of Nonatypical Endometrial Hyperplasia

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer announced today the start of its Phase III study SUNFLOWER, an investigational study evaluating the efficacy and safety of 52mg levonorgestrel-releasing intrauterine system Mirena® for the treatment of nonatypical endometrial hyperplasia (NAEH) in women. NAEH is an abnormal thickening of the lining of the uterus, known as the endometrium, due to an imbalance between estrogen and progesterone levels. This condition is classified as nonatypical as the cells...
Back to Newsroom